DurAVR isn't anywhere near the finish line yet.
Besides, the competition doesn't have to acquire a company with a better product - all they have to do is maintain market share, and they have their own R&D, their industry momentum and reputation to help with that.
Hospitals will want a product backed by a $multi-billion company: after all, if a heart-valve product is is implanted with adverse consequences, the lawyers have to sue someone for multi-millions, and we don't want that to be our hospital.
I'm not being a wet blanket for the fun of it. But there's an awful lot of chickens being counted around here.
P
DurAVR isn't anywhere near the finish line yet.Besides, the...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.00 |
Change
-0.150(0.99%) |
Mkt cap ! $317.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.10 | $14.85 | $133.6K | 8.912K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $14.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 510 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |